Weekly top stories in longevity science, geroscience, and human aging mitigation.
Longevity
Executive Summary The week of May 4 - May 11, 2026 was anchored by a single clinical readout that the geroscience field had been waiting on for months: BioAge Labs' Phase 1 data for the oral NLRP3 inhibitor BGE-102, showing a median 86% reduction in high-sensitivity C-reactive protein at
Longevity
Executive Summary This week the longevity field absorbed three structural shocks that, taken together, mark its transition from a hype-driven small-trial phase into a more disciplined translational regime. First, the long-anticipated RAPA-EX-01 trial of weekly oral sirolimus combined with exercise in older adults read out negatively across nearly every functional
Longevity
Executive Summary The week's geroscience output points toward a consolidation around two structural themes: the field is reaching consensus that single-pathway interventions (NAD+ boosting, autophagy upregulation, senescent-cell clearance alone) are not delivering the functional outcomes their mechanisms predict, and the regulatory infrastructure required to translate aging interventions into
Longevity
Executive Summary Longevity science is undergoing a simultaneous acceleration on two fronts: the translation of decades of molecular biology into actual human clinical trials, and a deepening philosophical and systems-level rethinking of what aging fundamentally is. This week's most significant stories reflect both pressures at once. The dominant